3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
127
Breast Neoplasms
127
Ovarian Neoplasms
79
Fallopian Tube Neoplasms
45
Lung Neoplasms
42
Carcinoma, Ovarian Epithelial
30
Uterine Cervical Neoplasms
27
Parkinson Disease 4, Autosomal Dominant Lewy Body
27
Endometrial Neoplasms
25
Triple Negative Breast Neoplasms
23
Neoplasm Metastasis
21
Neoplasms
20
Esophageal Neoplasms
19
Stomach Neoplasms
18
Esophageal Squamous Cell Carcinoma
15
Adenocarcinoma of Lung
13
Carcinoma
12
Brenner Tumor
11
Recurrence
10
Urinary Bladder Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
8
Head and Neck Neoplasms
8
Peritoneal Neoplasms
7
Inflammatory Breast Neoplasms
5
Carcinoma, Squamous Cell
5
Adenocarcinoma, Bronchiolo-Alveolar
5
Adenocarcinoma
5
Melanoma
4
Carcinoma, Ductal, Breast
4
Adenocarcinoma Of Esophagus
4
Interventions
Pemetrexed
3
Carboplatin
3
pembrolizumab
2
patritumab
1
osimertinib
1
napabucasin
1
camrelizumab
1
aflutinib
1
Vinorelbine
1
TNFSF10 protein, human
1
Paclitaxel
1
Injections
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Docetaxel
1
Cisplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Bronchial Neoplasms
×
Paclitaxel
×
Clear all
NCT02826161
2023-11-15
CanStem43L
Sumitomo Pharma America, Inc.
Phase 3
Terminated
4 enrolled
6 charts